A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 4, 1997, Pages 210-216

  Schenkein, David P ^a   Roitman, Daryl ^a   Miller, Kenneth B ^a   Morelli, Julie ^a   Stadtmauer, Edward ^b   Pecora, Andrew L ^c   Cassileth, Peter ^d   Fernandez, Hugo ^d   Cooper, Brenda W ^e   Kutteh, Leila ^e   Lazarus, Hillard M ^e  

^a TUFTS MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Lymphoma; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; RADIATION EXPOSURE; STANDARD; TREATMENT OUTCOME;

ADULT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUCOVORIN; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; METHOTREXATE; MIDDLE AGED; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0031242084     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Aisenberg, A: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 13:2656, 1995.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CAJ, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002, 1993.
3. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister A, Meerwaldt JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WS, Yeap BY: A predictive model for aggressive NHL: the international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 329:987, 1993.
4. Shipp M: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has high risk disease? Blood 83:1165, 1994.
5. Nademanee A, Schmidt GM, O'Donnell MR, Snyder DS, Parker PA, Stein A, Smith E, Lipsett JA, Sniecinski I, Margolin K, Somlo G, Niland JC, Blume KG, Forman SJ: High dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma. Blood 80:1130, 1992.
6. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Grandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G: High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med, 1997. 336: p. 1290-1297.
7. The non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 49:2112, 1982.
8. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860, 1971.
9. Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, Mcglave P, Lazarus HM: Recommended criteria for the performance of autologous and allogeneic bone marrow transplantation: a report from the Eastern Cooperative Oncology Group. Ann Intern Med 120:143, 1994.
10. Malacbowski M, Comenzo R, Hillyer C, Tiegerman K, Berkman E: Large volume leukaphersis for peripheral blood stem cell collection in patients with hematological malignancies. Transfusion 32:732, 1992.
11. Comenzo R, Malachowski M, Miller K, Erban J, Schenkein D, Desforges J, Berkman E: Engraftment with peripheral blood stem cells collected by large volume leukapheresis for patients with lymphoma. Transfusion 32:729, 1992.
12. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958.
13. Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Valagussa P, Bonadonna G: Prolonged disease free survival after high dose sequential chemo-radiotherapy and haemopoitic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 2:645, 1991.
14. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Stern P, Valagussa P, Bonadonna G: Prospective randomized comparison of MACOP-B vs rhGM-CSF-supported high dose sequential myeloablative chemo-radiotherapy in diffuse large cell lymphomas. Proc ASCO 13:373, 1994.
15. Armitage JO: Autologous bone marrow transplantation for patients with aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 1:62, 1992.
16. Gianni AM, Bregni M, Siena S, Orazi A, Stern A, Gandola L, Bonadonna G: Recombinant human granulocyte-macrophage colony stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 8:768, 1990.
17. Gianni AM, Bregni M, Siena S, Magni M, Di Nicola M, Lombardi F, Tarella C, Pileri A, Bonadonna G: Granulocyte macrophage colony stimulating factor or granulocyte colony stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol 10:1955, 1992.
18. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL: High dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an eastern cooperative oncology group protocol. J Clin Oncol 10:558, 1992.
19. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D, Sutcliffe SB, Keating A: High dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 11:704, 1993.
20. Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botta B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L: Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high risk diffuse large-cell lymphoma. J Clin Oncol 15:491, 1997.
21. Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemackers JM, van Oers RH, Haak HL, Schots R, Dekker AW, deGast GC, Lowenberg B: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045, 1995.